Immune Pharmaceuticals

Immune Pharmaceuticals to restructure

Tuesday, April 25, 2017

Immune Pharmaceuticals, a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced a major corporate restructuring with the objective of prioritizing and segregating its R&D efforts on a focused set of products in inflammatory disease and dermatology and strengthening its financial position. 

[Read More]

Immune Pharmaceuticals changes board of directors

Thursday, October 17, 2013

Immune Pharmaceuticals has announced that Rene Lerer, M.D., executive chairman of Magellan Health Services, and Daniel Kazado, senior advisor to Melini Capital, have joined the company’s board of directors. Lerer and Kazado replace Pierre Albouy and Herve de Kergrohen, who have resigned from the board but will continue as strategic advisors to the company.  The board will continue to consist of seven members.

[Read More]